Zyloric Dosage & Drug Information

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Allopurinol

Indications/Uses

Idiopathic gout, uric acid lithiasis, acute uric acid nephropathy; neoplastic & myeloproliferative disease w/ high cell turnover rates in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders ie, hypoxanthine guanine phosphoribosyltransferase eg, Lesch-Nyhan syndrome; glucose-6-phosphatase eg, glycogen storage disease; phosphoribosylpyrophosphate synthetase & amidotransferase; adenine phosphoribosyltransferase. Management of 2, 8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase; recurrent mixed Ca oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary & similar measures have failed.

Click to view Zyloric detailed prescribing information

Dosage/Direction for Use

Adult 100-200 mg daily in mild conditions, 300-600 mg daily in moderately severe conditions, or 2-10 mg/kg/day. Childn <15 yr 100-300 mg daily.

Click to view Zyloric detailed prescribing information

Overdosage

View Zyloric overdosage for action to be taken in the event of an overdose.

Administration

Should be taken with food.

Contraindications

Hypersensitivity.

Click to view Zyloric detailed prescribing information

Special Precautions

W/draw treatment immediately if hypersensitivity reactions including maculopapular exanthema, hypersensitivity syndrome & SJS/TEN occur. HLA-B*5801 allele carrier. Patients under treatment for HTN or cardiac insufficiency (eg, diuretics or ACE inhibitors). Increased risk of allopurinol induced SJS/TEN, & other serious hypersensitivity reactions in patients w/ chronic renal insufficiency & concomitant diuretic use, particularly thiazides. Not indicated for asymptomatic hyperuricaemia. Not to be started until an acute gout attack has completely subsided. Conditions w/ increased urate formation eg, malignant disease, Lesch-Nyhan syndrome; ensure adequate hydration. Impaction of uric acid renal stones. Increased TSH values on long-term use. May affect ability to drive & use machines. Renal & hepatic impairment. Pregnancy & lactation.

Click to view Zyloric detailed prescribing information

Use In Pregnancy & Lactation

Click to view Zyloric detailed prescribing information

Adverse Reactions

Rash.

Click to view Zyloric detailed prescribing information

Drug Interactions

Prolonged activity of 6-mercatopurine or azathioprine. Increases plasma t_½ of vidarabine. Decreased effect by uricosurics eg, probenecid & large doses of salicylates. Increased risk of prolonged hypoglycaemic activity w/ chlorpropamide. Increased effects of warfarin & other coumarin anticoagulants. Inhibited hepatic oxidation of phenytoin. Inhibition of theophylline metabolism. Increased frequency of skin rash w/ ampicillin or amoxicillin. Enhanced bone marrow suppression by cyclophosphamide & other cytotoxic agents. Increased plasma conc of cyclosporin. Co-administration w/ didanosine is generally not recommended. Increased serum urate & oxipurinol plasma conc w/ furosemide. Increased risk of hypersensitivity w/ diuretics eg, thiazides & ACE inhibitors especially in renal impairment.

Click to view Zyloric detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Zyloric detailed prescribing information

Storage

View Zyloric storage conditions for details to ensure optimal shelf-life.

Description

View Zyloric description for details of the chemical structure and excipients (inactive components).

Action

View Zyloric mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Hyperuricemia & Gout Preparations

ATC Classification

M04AA01 - allopurinol ; Belongs to the class of preparations inhibiting uric acid production. Used in the treatment of gout.

Regulatory Classification

Presentation/Packing

Form

Zyloric tab 100 mg

Packing/Price

200's;60's

Form

Zyloric tab 300 mg

Packing/Price

100's;30's

Zyloric

allopurinol

Manufacturer:

GlaxoSmithKline Indonesia